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Effectiveness of nivolumab in an elderly 
patient with metastatic BRAF-negative 
melanoma originating from the anal 
region
ABSTRACT
High serum concentration of lactate dehydrogenase (LDH) is associated with poor prognosis in patients with 
metastatic cutaneous melanoma. Herein, we present a case of a 92-year-old patient with metastatic melanoma 
and negative prognostic factors treated with anti-PD-1 antibody nivolumab. The therapy yielded excellent clinical 
results: significant regression of metastatic lesions and improvement in the patient’s performance status. The 
presented case confirms previously reported observations regarding high clinical activity and acceptable safety 
profile of nivolumab in elderly patients.
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Introduction
Malignant melanoma is a malignancy orginating from 
melanocytes. Skin is the most common site of melanoma, 
although possible locations also include mucosal mem-
branes, eyeball (choroid, ciliary body, iris), or central 
nervous system [1, 2]. Primary location of melanoma in 
the anal region is a scarcity because probably most of 
the melanomas in this region arise from skin without 
previous exposure to sunlight radiation (non-chronic sun 
damage; non-CSD). Usually, this subtype of melanoma is 
associated with more aggressive course of the disease than 
cutaneous melanoma linked to chronic sun damage [3]. 
Case report
We present a case of 92-year-old male, without 
comorbidities other than history of arterial hyperten-
sion, in whom cutaneous melanoma of the anal region 
was excised on 19 December 2012. Histopathological 
examination confirmed the diagnosis of cutaneous 
melanoma, with Breslow’s depth 2.3 mm, Clark’s level 
stage IV, and mitotic index 3/mm2. Chest X-ray and 
abdominal ultrasound examination showed no signs of 
metastatic spread. The patient underwent wide local 
excision and sentinel lymph node biopsy (SLNB) on 
19 February 2013, without the presence of melanoma 
within the excised scar and within two evaluated sen-
tinel lymph nodes. Afterwards, the patient remained 
under regular clinical surveillance. In April 2014 the 
presence of suspicious infiltration in the rectum was 
detected and examination from a specimen obtained 
via endoscopy for suspected presence of melanoma. On 
14 May 2014 abdominoperineal resection of the rectum 
with a formation of colostomy was performed. The 
pathology report of postoperative material confirmed 
the presence of melanoma infiltrates in the rectum and 
the presence of metastases in one out of five excised 
perirectal lymph nodes. In January 2016 new metastatic 
lesions were found in the groins and the patient under-
went bilateral inguinal lymphadenectomy. Melanoma 
metastases were confirmed in seven out of 10 lymph 
nodes examined from the left groin and in four of six 
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Figure 2. Right adrenal metastasis before (A) and 3 months after initiation of nivolumab (B)
A B
lymph nodes from the right groin. Due to the presence 
of melanoma infiltrates within capsules of excised lymph 
nodes, both inguinal regions were irradiated with 36 Gy 
in nine fractions as an adjuvant therapy.
The patient remained under observation until April 
2017, when a follow-up abdomen CT scan showed the 
presence of a metastatic lesion in the adrenal gland, lymph 
nodes along the iliac vessels, and recurrence in the rectum. 
Additionally, chest CT scan revealed numerous metasta-
ses in both lungs, up to 2.5 cm in diameter, and brain CT 
scan showed no signs of central nervous system metasta-
ses. Molecular analyses from previously obtained material 
excluded the presence of targetable BRAF mutation. 
Therefore, immunotherapy with nivolumab was 
initiated. The patient received first dose of nivolumab 
on 27 April 2017 and fortnightly afterwards on a regular 
basis. At the time of therapy introduction, laboratory anal-
yses showed leukopaenia of 2.12 × 103/µL, neutropaenia 
of 1.18 × 103/µL, highly elevated serum LDH level of 
890 U/L (with upper limit of 240 U/L), and liver enzymes 
over 1.5 times above the upper limit of normal. Further 
laboratory analyses done during therapy showed nor-
malisation of blood and biochemical parameters, which 
correlated with improvement in the patient’s performance 
status. First control CT scans performed on the 25th of 
July 2017 demonstrated regression of pulmonary lesions 
diameters (Fig. 1), as well as partial regression of metasta-
sis in right adrenal gland (Fig. 2) and regression of lesion 
in rectum (Fig. 3). Treatment tolerance was well and the 
patient currently continues treatment with nivolumab.
Summary
Cutaneous melanoma can be effectively treated with 
anti-PD-1 antibodies in elderly patients, even in the pres-
ence of negative prognostic factors such as elevated serum 
LDH concentration. Available literature reports suggest 
non-inferior outcomes with use of immunotherapy in pa-
tients aged over and under 70 years old [4, 5]. The presented 
case represents an excellent example of safe and effective 
treatment of an elderly patient with cutaneous melanoma. 
Currently, immunotherapy remains the treatment-of-choice 
in metastatic BRAF-negative melanoma [2, 6, 7]. 
Figure 1. Lung metastasis before (A) and 3 months after initiation of nivolumab (B)
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Figure 3. Metastases along iliac vessels before (A) and 3 months after initiation of nivolumab (B)
A B
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